Last-Resort drug linvoseltamab offered to myeloma patients with no other options
NCT ID NCT05164250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides linvoseltamab (REGN5458) to patients with relapsed or refractory multiple myeloma who have exhausted all standard treatments. The drug is a type of immunotherapy that helps the immune system attack cancer cells. It is given through compassionate use, meaning it is available outside of a clinical trial for those with no alternatives.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- linvoseltamab (REGN5458)
- What this could lead to
- If this treatment works, it could offer a new option for patients with multiple myeloma that has stopped responding to other therapies.
- What could go wrong
- This is a compassionate use program, not a formal trial, so data on safety and effectiveness is limited. The drug may not work for everyone and can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact